Cite
HARVARD Citation
Miglietta, F. et al. (n.d.). A composite prognostic model for overall survival (OS) based on residual cancer burden (RCB) and tumor-infiltrating lymphocytes (TILs) on residual disease (RCB+TIL) in HER2+ breast cancer patients treated with neoadjuvant therapy: a multicenter study. European journal of cancer. pp. S3-. [Online].